tbuckley/cabot-search huggingface dataset:
No evidence of association of human polyomaviruses V6, V7 and V12, and Saint Louis human polyomavirus with squamous cell carcinoma
Authors: S. Ribero, C. Costa, F. Sidoti, S. Osella-Abate, R. Senetta, P. Cassoni, M.T. Fierro, R. Cavallo
Journal: British Journal of Dermatology (2017)

Some viral proteins expressed by Human Polyomaviruses (HPyV) are known to be able to cause cancer. Besides Merkel-Cell-Polyoma-Virus (MCV), four new human polyomaviruses have been identified in the last years. In 2010, the Sixth and Seventh HPyV (HPyV6 and HPyV7) were discovered2. Similar to MCV, HPyV6 and HPyV7 seem to be constituents of the human skin microbiome. Co-infecting HPyVs may therefore act as a co-factor in the development of cancers, including those induced by other oncoviruses. Despite these observations, their role in cancer remains controversial.

This article is protected by copyright. All rights reserved.
Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy.
Authors: A. Bessudo, J. C. Bendell, N. Gabrail, M. V. Kopp, L. Mueller, L. L. Hart, V. I. Vladimirov, A. U. Pande, I. Gorbatchevsky, C. Eng
Journal: Journal of Clinical Oncology (2011)

3582 Background: ARQ 197 selectively inhibits the c-MET receptor tyrosine kinase (RTK) which has been implicated in tumor cell migration, invasion, proliferation, and angiogenesis. CPT-11 plus C is a standard of care for CPT-11-refractory mCRC pts with WT KRAS tumors. Resistance to C has been associated with activation of alternative RTK pathways including c-MET. We hypothesize that adding ARQ 197 to CPT-11 plus C may decrease resistance to C therapy and improve pt outcomes. Methods: The primary objectives of the phase I study were to evaluate safety and tolerability of ARQ 197 administered in combination with CPT-11 plus C, and to define a recommended phase II dose (RPTD). Pts with locally advanced or mCRC, who received > 1 prior line of chemotherapy, were KRAS WT and ECOG performance status < 2 were eligible. Cohorts of 3 pts each were treated with CPT-11 (180 mg/m2) and C (500 mg/m2) every 2 weeks along with escalating doses of ARQ 197 (120, 240, 360 mg) PO BID. Blood and tissue specimens were collected for PK, biomarker, and other analyses. If no DLTs were observed during the first 28-day cycle for all 3 cohorts, 360 mg BID would be defined as the RPTD. Radiographic responses were assessed every 8 weeks per RECIST v1.1. Results: Nine pts were treated. Median age: 53 yr (range 30-77); ECOG PS 0/1: 4/5; median prior therapies: 2 (range 1-4). No DLTs were observed. To date, 4 pts have discontinued (2 disease progression, 2 withdrew consent), and 5 pts remain on study for median duration of 5.5 months (4.1-9.2). Reported grade 3/4 adverse events included: neutropenia (3/4: 0/1), fatigue (3/4: 2/0), and one case each of grade 3 leucopenia, acneiform rash, vomiting, diarrhea, anemia and syncope. Preliminary efficacy data in 9 evaluable pts include 1 CR (after 4 cycles), 2 PR (after 2 cycles), 5 SD, and 1 PD as best response. Conclusions: The combination of ARQ 197 and CPT-11 plus C was well tolerated with encouraging preliminary antitumor activity in previously treated mCRC patients. The RPTD for ARQ 197 was 360 mg BID. The randomized phase II portion of the study continues accrual.
Clinicopathologic Features, Prognosis, and Therapeutic Responses in Patients with Granulomatous Mycosis Fungoides: A Single Center Experience From Memorial Sloan Kettering Cancer Center.
Authors: Janet Y. Li, Melissa Pulitzer, Patricia L. Myskowski, Steven Dusza, Steven M. Horwitz, Alison Moskowitz, Christiane Querfeld
Journal: Blood (2012)
TMOD-06. ADAPTIVE CULTURE TECHNIQUES FOR HIGH GRADE GLIOMA, MENINGIOMA AND BRAIN METASTASIS
Authors: Amin Kassam, Denise Coley
Journal: Neuro-Oncology (2016)

There is an increasing need to develop personalized oncological therapy utilizing in vitro and in vivo models. To do so it is helpful to specifically target the progenitor cell niche within a tumor, maintain the tumor microenvironment during tissue harvest, and culture the cells using progenitor cell enriching conditions. Two different techniques have been used with high-grade gliomas (HGGs): sphere/floating culture and adherent culture on laminin-coated plates. However, it remains unknown whether these techniques can be utilized for other major brain tumors, such as meningioma and brain metastasis. In this report we review our adaptive culture technique for meningiomas and brain metastases in comparison with HGGs. Preoperatively targeted tissue is harvested using a non-ablative suction and mechanical cutting device. Tissue is captured in a closed loop system to minimize atmospheric exposure and degradation. Tissue is maintained at 4 C, and constantly perfused by cold culture media. The tissue is transported to lab and processed into single cell suspension for subsequent sphere and laminin culture and ortho- and hetero-topic patient derived xenograft. Viable adherent and sphere cultures were established for all three tumor types. Intriguingly, meningiomas grew better as adherent culture, while brain metastases preferred floating culture. Specifics of the harvest and culture technique will be presented in detail. In addition, results of in vitro chemical imaging as well as xenograft data will be presented. We have demonstrated a successful close capture non-ablative harvest technique to be able to acquire viable tissue for cell culture of major brain tumors. We believe this represents a critical step toward better understanding the biology and the development of novel therapeutic targets for the treatment of these common brain tumors.
Comprehensive genomic profiling of uterine carcinosarcomas identifies potential targeted therapy opportunities
Authors: J.A. Elvin, L.M. Gay, C. Gunderson, M. Greenwade, S. Ramkissoon, S. Ali, J.-A. Vergilio, J. Suh, J.S. Ross, K.N. Moore
Journal: Annals of Oncology (2016)
SURG-02. UK LOW GRADE GLIOMA MANAGEMENT - A SURVEY OF NATIONAL PRACTICE
Authors: Dmitri Shastin
Journal: Neuro-Oncology (2016)

There remains a variation between clinical teams in their understanding and attitude regarding treatment options. We sought to obtain information about how LGG Neurosurgery & Oncology practice is shaped throughout the UK and how care is structured and delivered. Neurosurgical units in the UK were distributed a Society of British Neurological Surgeons approved questionnaire asking about LGG practices in their area. Paediatric hospitals were excluded. There was a 53.1% response rate. 41% of units see patients in specialised LGG clinics, 35% use neuro-oncology clinics, 24% review in general clinics. On average, 4 specialties will attend specialised clinics, 2 - neuro-oncology clinics, and only a neurosurgeon - general clinics. 76% of the units aim for primary resection where possible; only 12% will start by observing the tumour even if focal and deemed resectable. Units seeing patients in general clinics have more tendency to biopsy routinely at presentation (p=0.027). Most centres (88%) offer surgery via awake craniotomy – with a variety of testing methods used. A positive correlation between operative numbers and the ability to offer awake surgery was noted. Following surgery for LGG, 65% initially follow their patients with serial scans while the remainder may refer patients for consideration of adjuvant therapy. A large proportion of respondents confirmed that they provide specialist LGG services in established multidisciplinary environments. The majority of centres do recognise the value of upfront surgery with the aim of achieving significant bulk resection. The methodology surrounding awake craniotomy varies markedly across the UK centres. A unit-to-unit variation in the post-operative care of LGG patients was also noted, with disparity in which patients are referred for adjuvant therapy. This survey supports the establishment of a UK National LGG Working Group who can setup a regular National outcome audit & establish a National LGG Database.
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for the Treatment of Children with Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) In First Remission (CR1)
Authors: Farid Boulad, Nancy A Kernan, Peter G Steinherz, Susan E Prockop, Andromachi Scaradavou, Trudy N Small, Rachel Kobos, Neerav Shukla, Carolyn Doorish, Richard J. O'Reilly
Journal: Blood (2010)
The comparison between TP53 gene polymorphisms (c.[215G > C]) homozygotes and heterozygotes in breast cancer patients: a clinicopathological analysis
Authors: J. Huszno, E. Grzybowska, Z. Kolosza, M. Nycz Bochenek, J. Pamula Pilat, K. Tecza, E. Nowara
Journal: Annals of Oncology (2016)
Early Different Downstream Target of Glucocorticoid Receptor Contributing to Glucocorticoids Sensitivity in Kasumi-1 Cells
Authors: Wenbin Gu, Meng Li, Liang Liang, Jian Zhang, Chongye Guo, Zhikai Xing, Yongqing Lan, Sha Li, Yangyang Li, Ran Gao, Shuangli Mi
Journal: Blood (2016)
Analysis of BRAF V600E mutation status – concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapy
Authors: V.H. Haselmann, C. Gebhardt, I. Brechtel, A. Duda, A. Sucker, J. Utikal, D. Schadendorf, M. Neumaier
Journal: Annals of Oncology (2016)
Predictable Prognostic Factor of CD56 Expression in Acute Myeloid Leukemia with t(8:21) Including Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Deok-Hwan Yang, Yeung-Chul Mun, Ho-Jin Shin, Yeo-Kyeoung Kim, Je-Jung Lee, Choi-Young Jin, Chu-Myong Seong, Hyeoung-Joon Kim
Journal: Blood (2005)
Mechanisms of Plk4 haploinsufficiency in hepatocellular carcinogenesis
Authors: P. Wu, C. Rosario, J. Paderova, R. Gladdy, M. Ko, J. Squire, J. Dennis, C. Swallow
Journal: Journal of Clinical Oncology (2009)

11100 Background: The pathogenesis of hepatocellular carcinoma (HCC) is multifactorial and includes genetic predisposition, though the precise nature of the latter is as yet poorly understood. Mice heterozygous for the polo like kinase Plk4 develop spontaneous HCC and human HCC cases show a high rate of LOH (loss of heterozygosity) at the Plk4 locus. We hypothesize that Plk4 is a haploinsufficient tumor suppressor in man. The purpose of this study was to investigate the mechanisms by which a 50% reduction of Plk4 leads to carcinogenesis. Methods: We established Plk4 ± and Plk4 +/+ murine embryonic fibroblast cell lines (MEFs) in vitro. 5 of 5 Plk4 +/+ MEF lines senesced at passage 7–8 as expected, while 9 of 9 Plk4 ± MEF lines immortalized in culture under NIH 3T3 protocol. The latter were used at passage 15–20 for in vivo tumorigenesis studies. Results: Plk4 ± MEFs demonstrated increased ploidy with increased passage number. By passage 4, Plk4 ± MEFs showed a near tetraploid karyotype as well as multiple chromosomal rearrangements and deletions, as assessed by Spectral Karyotype (SKY) Analysis. 5 out of 9 late passage Plk4 ± MEF lines injected into NOD-SCID mice grew tumors, with a latency of 3 to 12 weeks. By contrast, injection of Plk4 +/+ MEFs yielded no tumors. Tumors generated from injection of Plk4 ± MEFs were harvested, cultured and submitted to SKY analysis; this showed increased clonal rearrangements and deletions compared to the parent cell lines. Conclusion: A 50% reduction in Plk4 expression results in immortalization, aneuploidy and chromosomal instability in vitro, and tumorigenicity in vivo. These results demonstrate that insufficient levels of Plk4, whether due to mutation or LOH, can contribute to the pathogenesis of HCC. No significant financial relationships to disclose.
TMOD-21. DEFINING THE GROWTH FACTOR NICHE THAT SUPPORTS GBM INITIATION
Authors: Alexandra Bohm, Michael Blough, Gregory Cairncross
Journal: Neuro-Oncology (2016)

It has been challenging to fully understand the initiation and progression of Glioblastoma Multiforme (GBM), as the early events in tumour development cannot be readily discerned. Although previous work has hypothesized that genetic alterations, such as chromosome 7 gain and chromosome 10 loss, are critical and conserved during tumour initiation in all GBMs, the functional roles of these events have not been characterized. We have developed a murine model which allows us to study the early stages of GBM initiation in vitro and interrogate the role of specific molecular events at different stages of tumour development. This model combines overexpression of platelet-derived growth factor-AA (PDGF-AA) with inactivation of the tumour suppressor protein, p53 (TP53); two genetic alterations which are alone sufficient to induce gliomagenesis. This model provides us with an opportunity to explore the roles of growth factor signaling and p53 in regulating brain tumour initiation in a murine system. In this model, cells from the subventricular zone (SVZ) of p53 null mice are cultured in PDGF-AA for several months. After this time the cells transform; becoming growth factor independent and tumorigenic. We have found that p53 null SVZ cells struggle to survive when cultured in PDGF-AA, but eventually adapt and resume proliferating. In contrast, p53 wildtype cells fail to recover and proliferate when cultured in PDGF-AA. However, when p53 wildtype cells are cultured in PDGF-AA with an additional growth factors, such as insulin, FGF, or EGF, the cells begin to proliferate again, suggesting that PDGF-AA alone is not sufficient to promote normal, healthy proliferation in this cell population in our model. This work may help us define the growth factor profiles that are necessary to sustain and promote proliferation of SVZ cells, as well as understand the roles of growth factors that are required for GBM tumorigenesis.
RARE-11. PERINATAL DIFFUSE INFILTRATING BRAINSTEM GLIOMA: CASE REPORT AND REVIEW OF THE LITERATURE
Authors: Catherine Miller, Christopher Moertel
Journal: Neuro-Oncology (2016)

Tumors located within the brainstem account for 10-15% of all childhood brain tumors with a mean age of diagnosis between 5-9 years. Neonatal congenital tumors differ from those in older children both in anatomical predilection and histological spectrum. Few perinatal brainstem tumors have been reported in the literature, with the majority being primitive neuroectodermal tumors. We present a review of the literature for all reported cases of perinatal brainstem tumors. We describe the clinical presentation of a male infant born at 38 4/7 weeks by normal spontaneous vaginal delivery to a 32 year-old female. Labor and delivery was induced due to maternal hypertension but was otherwise unremarkable. Apgar scores were 8 and 9 at 1 minute and 5 minutes, respectively. During initial breast feeding in the delivery room the patient began having expiratory grunting, sternal retractions, and desaturations. A MRI obtained on day 4 of life revealed an abnormal mass-like expansion involving the pons and medulla with T2-hyperintensity and no restricted diffusion or contrast enhancement. Family chose to withdraw supportive cares given the grim prognosis and the infant passed. Postmortem exam showed extensive enlargement centered in the pons and rostral medulla with extension into the cerebellar white matter and cerebral peduncles at the mesencephalic level. Histologic sections showed the tumor was consistent with a infiltrating astrocytoma with a significant element of microglia, particularly at the more infiltrative margins. Many of the neonatal brainstem tumors described in the literature are consistent with primitive neuroectodermal tumors, however, our case illustrates that diffuse infiltrating pontine gliomas can also occur in the neonatal period and should be considered on the differential for any brainstem lesion. Evidence suggests that these lesions are different from those occur in older children and may have different genetic aberrations more susceptible to treatment.
Pulmonary Perfusion Changes Following Single-Lung Transplantation
Authors: Joby Tsai, Steven P. Rowe, Lilja B. Solnes, Roberto A. Salas Fragomeni
Journal: Clinical Nuclear Medicine (2017)

Following single-lung transplantation (SLT), there is significant redistribution of flow preferentially to the transplanted lung. Altered lung perfusion leads to unusual results when performing pulmonary scintigraphy, which could result in interpretation errors. We present pulmonary scintigraphy images from a 67-year-old female patient with history of chronic obstructive pulmonary disease that were obtained before SLT, 10 days after SLT, and 3 months after SLT.
Phenotypical and Functional Characterization of in Vitro Expanded Bone Marrow-Derived Mesenchymal Stromal Cells from Patients with Crohn’s Disease
Authors: Maria Ester Bernardo, Maria Antonietta Avanzini, Rachele Ciccocioppo, Cesare Perotti, Angela Maria Cometa, Antonia Moretta, Monica Valli, Francesca Novara, Rita Maccario, Gino Roberto Corazza, Franco Locatelli
Journal: Blood (2008)
Acute Myeloid Leukemia with Erythroid Predominance: A Reassessment Using Criteria Revised in the 2016 World Health Organization Classification
Authors: Po-Shen Ko, Yao-Chung Liu, Chiu-Mei Yeh, Liang-Tsai Hsiao, Cheng-Hwai Tzeng, Jyh-Pyng Gau, Yuan-Bin Yu, Tzeon-Jye Chiou, Chia-Jen Liu, Po-Min Chen, Jin-Hwang Liu
Journal: Blood (2016)
Sirtuin 1 regulates cardiac electrical activity by deacetylating the cardiac sodium channel
Authors: Ajit Vikram, Christopher M Lewarchik, Jin-Young Yoon, Asma Naqvi, Santosh Kumar, Gina M Morgan, Julia S Jacobs, Qiuxia Li, Young-Rae Kim, Modar Kassan, Jing Liu, Mohanad Gabani, Ajay Kumar, Haider Mehdi, Xiaodong Zhu, Xiaoqun Guan, William Kutschke, Xiaoming Zhang, Ryan L Boudreau, Shengchuan Dai, Daniel S Matasic, Saet-Byel Jung, Kenneth B Margulies, Vikas Kumar, Markus M Bachschmid, Barry London, Kaikobad Irani
Journal: Nature Medicine (2017)
Role of Il-17 Varies at Different Periods After Hematopoietic Stem Cell Transplantation: Protection From Acute Graft-Versus-Host Disease and Exacerbation of Chronic Graft-Versus-Host Disease.
Authors: Rie Kuroda, Ryosei Nishimura, Katsuaki Sato, Hideaki Maeba, Kazuhito Naka, Shintaro Mase, Raita Araki, Yasuhiro Ikawa, Yoichiro Iwakura, Shoichi Koizumi, Akihiro Yachie
Journal: Blood (2010)
Quality management of cancer chemotherapy using the Plan-Do-Check-Act (PDCA) cycle method by chemotherapy team
Authors: Satoshi Hibi, Kenji Ina, Megumi Kabeya, Hiroki Inoue, Yuko Shirokawa, Masatoshi Nagaoka, Saori Yokoi, Ayaka Suzuki, Erina Niwa, Takae Kataoka, Shu Yuasa
Journal: Annals of Oncology (2016)
Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting
Authors: M. Siano, G. Infante, R. Miceli, C. Resteghini, L. Locati, L. Licitra, P. Bossi
Journal: Annals of Oncology (2016)
Catheptic Activities of Neoplasms and of the Tissues of Normal and Tumor-Bearing Mice Correlated with Histologic Changes
Authors: Mary E. Maver, Thelma B. Dunn, Antoinette Greco
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Catheptic Activities of Neoplasms and of the Tissues of Normal and Tumor-Bearing Mice Correlated with Histologic Changes Get access Mary E. Maver, Mary E. Maver Search for other works by this author on: Oxford Academic PubMed Google Scholar Thelma B. Dunn, Thelma B. Dunn Search for other works by this author on: Oxford Academic PubMed Google Scholar Antoinette Greco Antoinette Greco Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 1, August 1945, Pages 49–60, https://doi.org/10.1093/jnci/6.1.49 Published: 01 August 1945
Plasma YKL-40 as a biomarker for poor prognosis in patients with metastatic colorectal cancer treated with 3. line cetuximab and irinotecan
Authors: B.V. Jensen, K.-L.G. Spindler, I.J. Christensen, J.V. Schou, D.L. Nielsen, A. Jakobsen, E. Høgdall, P. Pfeiffer, M.K. Yilmaz, J. Johansen
Journal: Annals of Oncology (2016)
Attenuated airway hyperresponsiveness and mucus secretion in <scp>HDM</scp>‐exposed Igf1r‐deficient mice
Authors: S. Piñeiro‐Hermida, J. A. Gregory, I. P. López, R. Torrens, C. Ruíz‐Martínez, M. Adner, J. G. Pichel
Journal: Allergy (2017)

Asthma is a common chronic lung disease characterized by airflow obstruction, airway hyperresponsiveness (AHR), and airway inflammation. IGFs have been reported to play a role in asthma, but little is known about how the insulin-like growth factor 1 receptor (IGF1R) affects asthma pathobiology.Female Igf1r-deficient and control mice were intranasally challenged with house dust mite (HDM) extract or PBS five days per week for four weeks. Lung function measurements, and bronchoalveolar lavage fluid (BALF), serum, and lungs were collected on day 28 for further cellular, histological, and molecular analysis.Following HDM exposure, the control mice responded with a marked AHR and airway inflammation. The Igf1r-deficient mice exhibited an increased expression of the IGF system and surfactant genes, which were decreased in a similar manner for control and Igf1r-deficient mice after HDM exposure. On the other hand, the Igf1r-deficient mice exhibited no AHR, and a selective decrease in blood and BALF eosinophils, lung Il13 levels, collagen, and smooth muscle, as well as a significant depletion of goblet cell metaplasia and mucus secretion markers after HDM exposure. The Igf1r-deficient mice displayed a distinctly thinner epithelial layer than control mice, but this was not altered by HDM.Herein, we demonstrate by the first time that the Igf1r plays an important role in murine asthma, mediating both AHR and mucus secretion after HDM exposure. Thus, our study identifies IGF1R as a potential therapeutic target, not only for asthma but also for hypersecretory airway diseases.
Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and acute phase protein reaction (APPR): Pooled analysis of two phase 3 trials (ROMANA 1 and ROMANA 2)
Authors: D. Currow, J. Temel, A. Abernethy, J. Friend, R. Giorgino, K.C. Fearon
Journal: Annals of Oncology (2016)
TG101348: A Dual-Acting JAK2/FLT3 Small Molecule Kinase Inhibitor for the Treatment of AML.
Authors: Betty Tam, Chi Ching Mak, Silva Stoughton, Cyrus Virata, Dan Lohse, Ehab Hanna, Marcela Alomia, Catriona Jamieson, John Doukas, Glenn Noronha, Michael Martin, Richard Soll, John Hood
Journal: Blood (2007)
Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors
Authors: B. Savastano, C.M. Della Corte, F. Papaccio, V. Giuseppe, G. Esposito, M. Fasano, M. Orditura, F. De Vita, F. Ciardiello, F. Morgillo
Journal: Annals of Oncology (2016)